Clinical trial
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
NCT00424060 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00424060 |
|---|---|
| Title | Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma |
| Official title | Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Genetic, Other |
| Interventions | sagopilone, fluorescence in situ hybridization, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study |
| Enrollment | 38 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | Jan 18, 2007 |
| Last update posted | Sep 24, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: